Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326728 · ClinicalTrials.gov registry record
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
A clinical trial, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- 56
- Enrollment target
NCT01326728: Clinical Trial study, sponsored by National Cancer Institute (NCI).
NCT01326728 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326728 was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- 56 participants
- Enrollment target
Study Summary
Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people s cancer remains active (comes back or continues to spread) after an allotransplant, while other peoples cancer disappears and they are hopefully cured. National Institutes of Health (NIH) researchers are studying the reasons for these different treatment outcomes, and trying to develop better cancer treatments for people with active cancer after allotransplant. Researchers are collecting data from people who have had allotransplants for a cancer of the blood, whether or not the cancer is in remission, and from their donors. Those with active cancers may be eligible to participate in one of several NIH studies testing treatments for active cancer after allotransplant. Objectives: * To develop a systematic, comprehensive evaluation of individuals with relapsed malignant blood cancers after allotransplant (and, if available, their donors) to identify potential treatment study options * To compare the immune system after allotransplant between people whose cancers are growing with people whose cancers remain in remission. * To compare the immune system after cancer relapse/progression treatment between people whose cancer responds to treatment with those whose cancers continue to grow. Eligibility: * Individuals whose blood system cancer grows or comes back after receiving allotransplant treatment. * Individuals whose blood system cancer is responding or in remission 100 days or more after receiving allotransplant treatment. * Related stem-cell donors of eligible allotransplant recipients. Design: * Participants will be evaluated with a full physical examination, detailed medical history (for recipients, including a history of allotransplant treatment process, side-effects, etc.),
Interventions
- BIOLOGICAL Allogeneic stem cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2011-03-30 |
| Est. Completion | 2017-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326728
The ClinicalTrials.gov registry entry for NCT01326728 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic stem cell transplant is the first listed.
NCT01326728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326728 about?
NCT01326728 is a clinical study titled "Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation". Background: Allogeneic hematopoietic stem cell transplantation (or allotransplant; donor blood stem cells) have been used with varying degrees of success as an immune therapy for blood-system cancers (leukemias, myelodysplastic syndrome, lymphomas, multiple myeloma, etc.). Some people s cancer rema...
What is the current status of trial NCT01326728?
This trial is currently terminated. The enrollment target is 56 participants. The study started on 2011-03-30. Estimated completion is 2017-07-14.
What interventions are being tested in trial NCT01326728?
The interventions under investigation include: Allogeneic stem cell transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT01326728?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.